Abstract
Background: Ovarian cancer is the leading cause of death among all gynecological disorders. Aberrant glycosylation, or more specifically, increased sialylation of proteins has been observed in ovarian cancer. Several sialyltransferase genes have been shown to be up-regulated at both the mRNA and protein levels in a number of cancers, including that of the ovary. ST6GAL1 (β-galactosamide α2,6-sialyltranferase 1) gene expression has previously been shown to be upregulated in ovarian cancers of all major subtypes.
Methods: We have identified the sialome (i.e., sialic acid containing glycoproteins) of biological fluids from ovarian cancer patients and ovarian cancer cell lines utilizing tandem mass spectrometry as a potential pool of novel biomarker candidates. The sialoglycopeptides from four ovarian cancer cell lines, pooled ascites (n=13) and ovarian cyst (n=14) fluids from ovarian cancer patients were enriched utilizing affinity to agarose-immobilized Elderberry lectin (Sambucus nigra agglutinin) and magnetic hydrazide beads folowing periodate-mediated oxidation of sialic acids. Benign ovarian cyst (n=10) and peritoneal effusion (n=20) fluids were analyzed in the same fashion to serve as controls. PNGase F deglycosylated peptides were identified using electrospray ionization-LTQ Orbitrap tandem mass spectrometry.
Results: In all of the samples analyzed in the glycoproteomic portion of the study, we have identified 579 glycosylation sites on 333 proteins. Of these, 13 were exclusively identified in biological fluids from ovarian cancer patients, and another eight were common to these fluids and the ovarian cancer cell line supernatants.
Conclusions: The proteins identified in the present study could form the basis for future studies examining and quantifying their sialylation status as biomarkers of ovarian cancer.
Conflict of interest statement
Authors conflict of interest disclosure: The authors stated that there are no conflicts of interest regarding the publication of this article.
Research funding: None declared.
Employment or leadership: None declared.
Honorarium: None declared.
References
1. Bast RC Jr, Badgwell D, Lu Z, Marquez R, Rosen D, Liu J, et al. New tumor markers: CA125 and beyond. Int J Gynecol Cancer 2005;15(Suppl 3):274–81.10.1111/j.1525-1438.2005.00441.xSearch in Google Scholar PubMed
2. Bast RC Jr. Status of tumor markers in ovarian cancer screening. J Clin Oncol 2003;21:200s–5s.10.1200/JCO.2003.01.068Search in Google Scholar PubMed
3. Cummings RD. The repertoire of glycan determinants in the human glycome. Mol Biosyst 2009;5:1087–104.10.1039/b907931aSearch in Google Scholar PubMed
4. Drake PM, Cho W, Li B, Prakobphol A, Johansen E, Anderson NL, et al. Sweetening the pot: adding glycosylation to the biomarker discovery equation. Clin Chem 2010;56:223–36.10.1373/clinchem.2009.136333Search in Google Scholar PubMed PubMed Central
5. Hedlund M, Ng E, Varki A, Varki NM. Alpha 2–6-Linked sialic acids on N-glycans modulate carcinoma differentiation in vivo. Cancer Res 2008;68:388–94.10.1158/0008-5472.CAN-07-1340Search in Google Scholar PubMed
6. Wang PH, Lee WL, Juang CM, Yang YH, Lo WH, Lai CR, et al. Altered mRNA expressions of sialyltransferases in ovarian cancers. Gynecol Oncol 2005;99:631–9.10.1016/j.ygyno.2005.07.016Search in Google Scholar PubMed
7. Lukk M, Kapushesky M, Nikkila J, Parkinson H, Goncalves A, Huber W, et al. A global map of human gene expression. Nat Biotechnol 2010;28:322–4.10.1038/nbt0410-322Search in Google Scholar PubMed PubMed Central
8. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004;3:Art. 3.10.2202/1544-6115.1027Search in Google Scholar PubMed
9. Drake PM, Schilling B, Niles RK, Braten M, Johansen E, Liu H, et al. A lectin affinity workflow targeting glycosite-specific, cancer-related carbohydrate structures in trypsin-digested human plasma. Anal Biochem 2011;408:71–85.10.1016/j.ab.2010.08.010Search in Google Scholar PubMed PubMed Central
10. Wang PH, Lo WL, Hsu CC, Lin TW, Lee WL, Wu CY, et al. Different enzyme activities of sialyltransferases in gynecological cancer cell lines. Eur J Gynaecol Oncol 2002;23:221–6.Search in Google Scholar
11. Saldova R, Wormald MR, Dwek RA, Rudd PM. Glycosylation changes on serum glycoproteins in ovarian cancer may contribute to disease pathogenesis. Dis Markers 2008;25: 219–32.10.1155/2008/601583Search in Google Scholar PubMed PubMed Central
12. Christie DR, Shaikh FM, Lucas JAt, Lucas JA 3rd, Bellis SL. ST6Gal-I expression in ovarian cancer cells promotes an invasive phenotype by altering integrin glycosylation and function. J Ovarian Res 2008;1:3.10.1186/1757-2215-1-3Search in Google Scholar
13. Swindall AF, Bellis SL. Sialylation of the Fas death receptor by ST6Gal-I provides protection against Fas-mediated apoptosis in colon carcinoma cells. J Biol Chem 2011;286:22982–90.10.1074/jbc.M110.211375Search in Google Scholar
14. Liu Z, Swindall AF, Kesterson RA, Schoeb TR, Bullard DC, Bellis SL. ST6Gal-I regulates macrophage apoptosis via alpha2–6 sialylation of the TNFR1 death receptor. J Biol Chem 2011;286:39654–62.10.1074/jbc.M111.276063Search in Google Scholar
15. Kuzmanov U, Jiang N, Smith CR, Soosaipillai A, Diamandis EP. Differential N-glycosylation of kallikrein 6 derived from ovarian cancer cells or the central nervous system. Mol Cell Proteomics 2009;8:791–8.10.1074/mcp.M800516-MCP200Search in Google Scholar
16. Kuzmanov U, Smith CR, Batruch I, Soosaipillai A, Diamandis A, Diamandis EP. Separation of kallikrein 6 glycoprotein subpopulations in biological fluids by anion-exchange chromatography coupled to ELISA and identification by mass spectrometry. Proteomics 2012;12:799–809.10.1002/pmic.201100371Search in Google Scholar
17. Kuk C, Kulasingam V, Gunawardana CG, Smith CR, Batruch I, Diamandis EP. Mining the ovarian cancer ascites proteome for potential ovarian cancer biomarkers. Mol Cell Proteomics 2009;8:661–9.10.1074/mcp.M800313-MCP200Search in Google Scholar
18. Sarria A, Moreno LA, Mur M, Lazaro A, Lasierra MP, Roda L, et al. Relationship between immunoinflammatory proteins containing sialic acid and low-density lipoprotein serum concentrations. Clin Chim Acta 1996;252:21–31.10.1016/0009-8981(96)06307-3Search in Google Scholar
19. Shield-Artin KL, Bailey MJ, Oliva K, Liovic AK, Barker G, Dellios NL, et al. Identification of ovarian cancer-associated proteins in symptomatic women: a novel method for semi-quantitative plasma proteomics. Proteomics Clin Appl 2012;6:170–81.10.1002/prca.201100008Search in Google Scholar PubMed
20. Dieplinger H, Ankerst DP, Burges A, Lenhard M, Lingenhel A, Fineder L, et al. Afamin and apolipoprotein A-IV: novel protein markers for ovarian cancer. Cancer Epidemiol Biomarkers Prev 2009;18:1127–33.10.1158/1055-9965.EPI-08-0653Search in Google Scholar PubMed
21. Jackson D, Craven RA, Hutson RC, Graze I, Lueth P, Tonge RP, et al. Proteomic profiling identifies afamin as a potential biomarker for ovarian cancer. Clin Cancer Res 2007;13:7370–9.10.1158/1078-0432.CCR-07-0747Search in Google Scholar PubMed
22. Abdullah-Soheimi SS, Lim BK, Hashim OH, Shuib AS. Patients with ovarian carcinoma excrete different altered levels of urine CD59, kininogen-1 and fragments of inter-alpha-trypsin inhibitor heavy chain H4 and albumin. Proteome Sci 2010;8:58.10.1186/1477-5956-8-58Search in Google Scholar
23. Meri S, Lehto T, Sutton CW, Tyynela J, Baumann M. Structural composition and functional characterization of soluble CD59: heterogeneity of the oligosaccharide and glycophosphoinositol (GPI) anchor revealed by laser-desorption mass spectrometric analysis. Biochem J 1996;316:923–35.10.1042/bj3160923Search in Google Scholar
24. Yang GF, Li XM, Xie D. Overexpression of clusterin in ovarian cancer is correlated with impaired survival. Int J Gynecol Cancer 2009;19:1342–6.10.1111/IGC.0b013e3181a83ed9Search in Google Scholar
25. Yokoyama M, Matsue H, Muramoto K, Sasaki M, Ono K, Endo M. Isolation and characterization of sulfated glycoprotein from human pancreatic juice. Biochim Biophys Acta 1988;967:34–42.10.1016/0304-4165(88)90185-7Search in Google Scholar
26. Hough C, Cho K, Zonderman A, Schwartz D, Morin P. Coordinately up-regulated genes in ovarian cancer. Cancer Res 2001;61:3869–76.Search in Google Scholar
27. Losch A, Schindl M, Kohlberger P, Lahodny J, Breitenecker G, Horvat R, et al. Cathepsin D in ovarian cancer: prognostic value and correlation with p53 expression and microvessel density. Gynecol Oncol 2004;92:545–52.10.1016/j.ygyno.2003.11.016Search in Google Scholar PubMed
28. Okude M, Yamanaka A, Morimoto Y, Akihama S. Sialic acid in fibrinogen: effects of sialic acid on fibrinogen-fibrin conversion by thrombin and properties of asialofibrin clot. Biol Pharm Bull 1993;16:448–52.10.1248/bpb.16.448Search in Google Scholar PubMed
29. Seebacher V, Polterauer S, Grimm C, Husslein H, Leipold H, Hefler-Frischmuth K, et al. The prognostic value of plasma fibrinogen levels in patients with endometrial cancer: a multi-centre trial. Br J Cancer 2010;102:952–6.10.1038/sj.bjc.6605547Search in Google Scholar PubMed PubMed Central
30. Saldova R, Royle L, Radcliffe CM, Abd Hamid UM, Evans R, Arnold JN, et al. Ovarian cancer is associated with changes in glycosylation in both acute-phase proteins and IgG. Glycobiology 2007;17:1344–56.10.1093/glycob/cwm100Search in Google Scholar PubMed
31. Ferdeghini M, Gadducci A, Prontera C, Annicchiarico C, Gagetti O, Bianchi M, et al. Preoperative serum intercellular adhesion molecule-1 (ICAM-1) and E-selectin (endothelial cell leukocyte adhesion molecule, ELAM-1) in patients with epithelial ovarian cancer. Anticancer Res 1995;15:2255–60.Search in Google Scholar
32. Amankwah EK, Wang Q, Schildkraut JM, Tsai YY, Ramus SJ, Fridley BL, et al. Polymorphisms in stromal genes and susceptibility to serous epithelial ovarian cancer: a report from the Ovarian Cancer Association Consortium. PLoS One 2011;6:e19642.Search in Google Scholar
33. Karlsson NG, McGuckin MA. O-linked glycome and proteome of high molecular mass proteins in human ovarian cancer ascites: identification of sulfation, disialic acid and O-linked fucose. Glycobiology 2012;22:918–29.10.1093/glycob/cws060Search in Google Scholar PubMed
34. Jankovic MM, Milutinovic BS. Glycoforms of CA125 antigen as a possible cancer marker. Cancer Biomark 2008;4:35–42.10.3233/CBM-2008-4104Search in Google Scholar
35. Mitic N, Milutinovic B, Jankovic M. Assessment of sialic acid diversity in cancer- and non-cancer related CA125 antigen using sialic acid-binding Ig-like lectins (Siglecs). Dis Markers 2012;32:187–94.10.1155/2012/309203Search in Google Scholar
36. Ju W, Yoo BC, Kim IJ, Kim JW, Kim SC, Lee HP. Identification of genes with differential expression in chemoresistant epithelial ovarian cancer using high-density oligonucleotide microarrays. Oncol Res 2009;18:47–56.10.3727/096504009789954672Search in Google Scholar
37. Partheen K, Levan K, Osterberg L, Claesson I, Fallenius G, Sundfeldt K, et al. Four potential biomarkers as prognostic factors in stage III serous ovarian adenocarcinomas. Int J Cancer 2008;123:2130–7.10.1002/ijc.23758Search in Google Scholar
38. Shori DK, Genter T, Hansen J, Koch C, Wyatt H, Kariyawasam HH, et al. Altered sialyl- and fucosyl-linkage on mucins in cystic fibrosis patients promotes formation of the sialyl-Lewis X determinant on salivary MUC-5B and MUC-7. Pflugers Arch 2001;443(Suppl 1):S55–61.10.1007/s004240100645Search in Google Scholar
39. Budai L, Ozohanics O, Ludanyi K, Drahos L, Kremmer T, Krenyacz J, et al. Investigation of genetic variants of alpha-1 acid glycoprotein by ultra-performance liquid chromatography-mass spectrometry. Anal Bioanal Chem 2009;393:991–8.10.1007/s00216-008-2518-6Search in Google Scholar
40. Imre T, Kremmer T, Heberger K, Molnar-Szollosi E, Ludanyi K, Pocsfalvi G, et al. Mass spectrometric and linear discriminant analysis of N-glycans of human serum alpha-1-acid glycoprotein in cancer patients and healthy individuals. J Proteomics 2008;71:186–97.10.1016/j.jprot.2008.04.005Search in Google Scholar
41. Sarrats A, Saldova R, Pla E, Fort E, Harvey DJ, Struwe WB, et al. Glycosylation of liver acute-phase proteins in pancreatic cancer and chronic pancreatitis. Proteomics Clin Appl 2010;4:432–48.10.1002/prca.200900150Search in Google Scholar
42. Behrendt N, Ronne E, Ploug M, Petri T, Lober D, Nielsen LS, et al. The human receptor for urokinase plasminogen activator. NH2-terminal amino acid sequence and glycosylation variants. J Biol Chem 1990;265:6453–60.10.1016/S0021-9258(19)39348-2Search in Google Scholar
43. Henic E, Borgfeldt C, Christensen IJ, Casslen B, Hoyer-Hansen G. Cleaved forms of the urokinase plasminogen activator receptor in plasma have diagnostic potential and predict postoperative survival in patients with ovarian cancer. Clin Cancer Res 2008;14:5785–93.10.1158/1078-0432.CCR-08-0096Search in Google Scholar PubMed
44. Tetu B, Popa I, Bairati I, L’Esperance S, Bachvarova M, Plante M, et al. Immunohistochemical analysis of possible chemoresistance markers identified by micro-arrays on serous ovarian carcinomas. Mod Pathol 2008;21:1002–10.10.1038/modpathol.2008.80Search in Google Scholar PubMed
45. Lorkova L, Pospisilova J, Lacheta J, Leahomschi S, Zivny J, Cibula D, et al. Decreased concentrations of retinol-binding protein 4 in sera of epithelial ovarian cancer patients: a potential biomarker identified by proteomics. Oncol Rep 2011;27:318–24.Search in Google Scholar
46. L’Esperance S, Popa I, Bachvarova M, Plante M, Patten N, Wu L, et al. Gene expression profiling of paired ovarian tumors obtained prior to and following adjuvant chemotherapy: molecular signatures of chemoresistant tumors. Int J Oncol 2006;29:5–24.10.3892/ijo.29.1.5Search in Google Scholar
47. Normandin K, Peant B, Le Page C, de Ladurantaye M, Ouellet V, Tonin PN, et al. Protease inhibitor SERPINA1 expression in epithelial ovarian cancer. Clin Exp Metastasis 2010;27:55–69.10.1007/s10585-009-9303-6Search in Google Scholar PubMed
48. Jinawath N, Vasoontara C, Jinawath A, Fang X, Zhao K, Yap KL, et al. Oncoproteomic analysis reveals co-upregulation of RELA and STAT5 in carboplatin resistant ovarian carcinoma. PLoS One 2010;5:e11198.10.1371/journal.pone.0011198Search in Google Scholar PubMed PubMed Central
49. Davidson B, Stavnes HT, Holth A, Chen X, Yang Y, Shih Ie M, et al. Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from breast carcinoma in effusions. J Cell Mol Med 2010;15:535–44.10.1111/j.1582-4934.2010.01019.xSearch in Google Scholar
50. Gornik O, Lauc G. Enzyme linked lectin assay (ELLA) for direct analysis of transferrin sialylation in serum samples. Clin Biochem 2007;40:718–23.10.1016/j.clinbiochem.2007.01.010Search in Google Scholar PubMed
51. Hogdall C, Fung ET, Christensen IJ, Nedergaard L, Engelholm SA, Petri AL, et al. A novel proteomic biomarker panel as a diagnostic tool for patients with ovarian cancer. Gynecol Oncol 2011;123:308–13.10.1016/j.ygyno.2011.07.018Search in Google Scholar PubMed
52. Secord AA, Darcy KM, Hutson A, Lee PS, Havrilesky LJ, Grace LA, et al. Co-expression of angiogenic markers and associations with prognosis in advanced epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol 2007;106:221–32.10.1016/j.ygyno.2007.03.021Search in Google Scholar PubMed
53. Ahn HJ, Kim YS, Lee CH, Cho EW, Yoo HS, Kim SH, et al. Generation of antibodies recognizing an aberrant glycoform of human tissue inhibitor of metalloproteinase-1 (TIMP-1) using decoy immunization and phage display. J Biotechnol 2010;151:225–30.10.1016/j.jbiotec.2010.12.004Search in Google Scholar PubMed
54. Karam AK, Santiskulvong C, Fekete M, Zabih S, Eng C, Dorigo O. Cisplatin and PI3kinase inhibition decrease invasion and migration of human ovarian carcinoma cells and regulate matrix-metalloproteinase expression. Cytoskeleton (Hoboken) 2010;67:535–44.10.1002/cm.20465Search in Google Scholar PubMed PubMed Central
55. Mohamed E, Abdul-Rahman PS, Doustjalali SR, Chen Y, Lim BK, Omar SZ, et al. Lectin-based electrophoretic analysis of the expression of the 35 kDa inter-alpha-trypsin inhibitor heavy chain H4 fragment in sera of patients with five different malignancies. Electrophoresis 2008;29:2645–50.10.1002/elps.200700828Search in Google Scholar PubMed
56. Hellstrom I, Raycraft J, Hayden-Ledbetter M, Ledbetter J, Schummer M, McIntosh M, et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res 2003;63:3695–700.Search in Google Scholar
57. Schummer M, Drescher C, Forrest R, Gough S, Thorpe J, Hellstrom I, et al. Evaluation of ovarian cancer remission markers HE4, MMP7 and Mesothelin by comparison to the established marker CA125. Gynecol Oncol 2011;125:65–9.10.1016/j.ygyno.2011.11.050Search in Google Scholar PubMed PubMed Central
©2013 by Walter de Gruyter Berlin Boston